Ireland
--:--IST
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

TEV-56278 clinical trials

Also listed in trial records as Intervention1:FXB0871, Intervention2:FXB0871, Intervention3:FXB0871, Intervention4:FXB0871
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA, Canada and China registers that name TEV-56278 as an intervention. Synced 2 Oct 2026
2Current trials
1Recruiting now
2Lead sponsors
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Last verified · Editorial standards
At a glance

TEV-56278 is named as an intervention in 2 current clinical trials in our USA, Canada and China registers. 1 is recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is Teva Branded Pharmaceutical Products R&D LLC (1). The most-studied condition is Advanced Solid Tumors.

Trials by status

  • Recruiting150%
  • Not yet open150%

Trials by phase

  • Phase 12100%
01

Clinical trials of TEV-56278

2 trials
StudyPhaseStatusLead sponsorRegisters

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with TEV-56278

4 conditions
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Teva Branded Pharmaceutical Products R&D LLC1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd1
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA11
Clinical trials in Canada11
Clinical trials in China10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about TEV-56278 trials

How many clinical trials are testing TEV-56278?

2 current trials in our USA, Canada and China registers name TEV-56278 (also registered as Intervention1:FXB0871) as a drug or biological intervention, as of the registry sync on 2 October 2026. Completed and withdrawn studies are not counted.

Are TEV-56278 trials recruiting patients?

Yes. 1 of the 2 trials is recruiting: 1 with sites in USA and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors TEV-56278 clinical trials?

Teva Branded Pharmaceutical Products R&D LLC (1) and Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how TEV-56278 works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how TEV-56278 works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists TEV-56278 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 2 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.